<DOC>
	<DOCNO>NCT00728455</DOCNO>
	<brief_summary>This trial conduct United States America ( USA ) . The aim clinical trial investigate whether NNC 0070-0002-0349 safe well tolerate . Groups eight subject administer subcutaneous injection NNC 0070-0002-0349 placebo Day 1 begin low dose ; laboratory vital sign data well subject report adverse event evaluate . If safe proceed , next group subject give high dose safety evaluation perform proceed . In total , 5 dose level evaluate . Subjects administer dose remain clinic morning Day 8 dose vital sign safety labs well blood draw pharmacokinetic sample take . Subjects return clinic Days 10 , 12 , 14 , 16 , 18 22 repeat blood draw safety lab . Day 22 final study visit .</brief_summary>
	<brief_title>Examination Safety Tolerability NNC 0070-0002-0349 Overweight/Obese Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Nutrition Disorders</mesh_term>
	<criteria>BMI great 27.0 less 35.0 kg/m2 Systolic blood pressure great 140 mm Hg diastolic great 90 mm Hg Depression suicidal thought ( Scoring Patient Health Questionnaire9item ) Eating disorder Unusual diet eat habit Dieting , use diet drug obesity surgery Diabetes history abnormal fasting glucose</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>